Venetoclax Use in Paediatric Haemato-Oncology Centres in Poland: A 2022 Survey.

ABSTRACT: Venetoclax, the best established BH3-mimetic, is a practice-changing proapoptotic drug in blood cancers in adults. In paediatrics the data are fewer but exciting results were recently presented in relapsed or refractory leukaemias demonstrating significant clinical activity. Importantly, the in-terventions could be potentially molecularly guided as vulnerabilities to BH3-mimetics were re-ported. Currently venetoclax is not incorporated into paediatric treatment schedules in Poland but it has been already used in patients that failed conventional therapy in Polish paediatric haemato-oncology departments. The aim of the study was to gather clinical data and correlates of all paediatric patients treated so far with venetoclax in Poland. We set out to gather this experience to help choose the

SUBMITTER: Bobeff K 

PROVIDER: S-EPMC10137026 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature